Concepedia

Author

Parul Doshi

Janssen (United States)ORCID

Also Known As

Doshi, P, P Doshi, P. Doshi, PD Doshi, Parul D Doshi, Parul Doshi

89

Publications

2.9K

Citations

25

H-Index

53

Concepts

All Affiliations

Janssen (United States)Bristol-Myers Squibb (United States)Icahn School of Medicine at Mount SinaiEmory UniversityGenmab (Netherlands)
PD

About

Parul Doshi is an author at Janssen (United States) specializing in medicine, immunology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

360

2

Health Sciences

3

3

74

3

Cell Biology

2

2

100

4

Natural Sciences

1

1

31

5

Hepatology

1

1

17

Parul Doshi

×

34

Publications

2.7K

Citations

23

H-Index

YearCitations

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu,

Annals of Oncology

2021

263

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Inger S. Nijhof, Richard W.J. Groen, H M Lokhorst,

Leukemia

2015

261

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko, Keunchil Park, Ramaswamy Govindan,

Journal of Clinical Oncology

2021

254

Resolving the daratumumab interference with blood compatibility testing

Claudia I. Chapuy, Rachel T. Nicholson, Maria Aguad,

Transfusion

2015

232

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

Simon Papillon‐Cavanagh, Parul Doshi, Radu Dobrin,

ESMO Open

2020

227

Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

Jeroen Lammerts van Bueren, Danielle Jakobs, Niels Kaldenhoven,

Blood

2014

217

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

M. van Oostendorp, Jeroen J. Lammerts van Bueren, Parul Doshi,

Transfusion

2015

151

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

François Moisan, E. Brian Francisco, Anamaria Brozović,

Molecular Oncology

2014

115

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages

Kelly Kersten, Seth B. Coffelt, Marlous Hoogstraat,

OncoImmunology

2017

100

International validation of a dithiothreitol (DTT)‐based method to resolve the daratumumab interference with blood compatibility testing

Claudia I. Chapuy, Maria Aguad, Rachel T. Nicholson,

Transfusion

2016

96

Page 1